Skip to main content
NewslettersWatchlist

Abbott Laboratories(ABT-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low113.20
Day High114.16
Open:113.75
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

Abbott Laboratories raises annual profit forecast as strong medical device sales power quarterly beat

Abbott now expects a profit of $4.61 to $4.71 per share for the full year, compared with its prior forecast of $4.55 to $4.70
Barchart
Stocks Soar Before the Open as Fed’s Big Rate Cut Boosts Sentiment, U.S. Economic Data and FedEx Earnings on Tap
Motley Fool
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
Motley Fool
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Motley Fool
3 Stocks to Buy and Hold Forever
Motley Fool
3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold
Motley Fool
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
Barchart
3 Recession-Proof Dividend Kings to Buy For a Lifetime of Income
Motley Fool
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
Motley Fool
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
Motley Fool
3 Unstoppable Dividend Stocks to Buy Right Now
Motley Fool
Looking for Safe Dividend Income? These 3 Stocks Have Rock-Solid Payouts.
Newswire.ca
Abbott's AVEIR™ DR - World's First Dual Chamber Leadless Pacemaker System - Now Available in Canada
Barchart
3 Dividend Kings With Massive Dividend Growth Rates
Motley Fool
Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?
Barchart
Nervous About the Market? 3 Defensive Stock Picks to Consider This August
Motley Fool
3 Stocks Retirees Should Absolutely Love
Newswire.ca
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Newswire.ca
Quebec Expands Public Reimbursement of Abbott's FreeStyle Libre® 2 Flash Glucose Monitoring System to More Adults with Diabetes
Motley Fool
Chips, Glorious Chips!
Motley Fool
3 Dividend Growth Stocks to Buy Hand Over Fist in August
Motley Fool
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.

Profile

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.